Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Equity (2016 - 2025)

Avalo Therapeutics' Return on Equity history spans 11 years, with the latest figure at 0.9% for Q4 2025.

  • For Q4 2025, Return on Equity fell 44.0% year-over-year to 0.9%; the TTM value through Dec 2025 reached 0.9%, down 44.0%, while the annual FY2025 figure was 0.72%, 22.0% down from the prior year.
  • Return on Equity reached 0.9% in Q4 2025 per AVTX's latest filing, up from 1.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 2.74% in Q2 2023 to a low of 6.05% in Q3 2023.
  • Average Return on Equity over 5 years is 0.31%, with a median of 0.01% recorded in 2022.
  • Peak YoY movement for Return on Equity: crashed -607bps in 2023, then skyrocketed 392bps in 2024.
  • A 5-year view of Return on Equity shows it stood at 0.0% in 2021, then soared by 2086bps to 0.02% in 2022, then plummeted by -17701bps to 2.87% in 2023, then skyrocketed by 84bps to 0.46% in 2024, then crashed by -97bps to 0.9% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Return on Equity are 0.9% (Q4 2025), 1.02% (Q3 2025), and 0.41% (Q2 2025).